Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.

导出 OA

翻译打印收藏纠错

作者： Chiara,Fischer ^[1] ; Thomas M,Deutsch ^[2] ; Manuel,Feisst ^[3] ; Nathalie,Rippinger ^[1] ; Fabian,Riedel ^[1] ; Andreas D,Hartkopf ^[4] ; Sara Y,Brucker ^[4] ; Christoph,Domschke ^[1] ; Carlo,Fremd ^[5] ; Laura,Michel ^[5] ; Barbara,Burwinkel ^[6] ; Andreas,Schneeweiss ^[5] ; Andrey,Turchinovich ^[6] ; Markus,Wallwiener ^[6]

作者单位： Department of Obstetrics and Gynecology, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. ^[1] Department of Obstetrics and Gynecology, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany. thomas.deutsch@med.uni-heidelberg.de. ^[2] Institute of Medical Biometry, University of Heidelberg, Im Neuenheimer Feld 130.3, 69120, Heidelberg, Germany. ^[3] Department of Obstetrics and Gynecology, University of Tübingen, Calwerstraße 7, 72076, Tübingen, Germany. ^[4] National Center for Tumor Diseases, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. ^[5] Molecular Epidemiology C080, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. ^[6]

关键词 Circulating microRNAs Liquid biopsy Metastatic breast cancer Survival miR-200 family

主题词乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);微RNAs(MicroRNAs);肿瘤复发, 局部(Neoplasm Recurrence, Local);预后(Prognosis)

DOI 10.1007/s00404-022-06442-2

PMID 35237856

发布时间 2022-09-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交